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Key Points
•We present real-world
data on all ruxolitinib-
treated myelofibrosis
patients in a 10-million-
resident region, with
a follow-up of 2 years.
•We found no evidence
of an increased risk of
developing lymphomas.
Introduction
Myeloproliferative neoplasms (MPNs) are clonal disorders that include polycythemia vera (PV), essential
thrombocythemia (ET), and primary myelofibrosis (PMF). Patients with MPNs have a higher risk than the
general population of developing a lymphoid neoplasm.1 It is still unclear whether this holds true for
nonhematological second primary malignancies (SPMs).2-4 However, among 20250 MPN patients
included in the Surveillance, Epidemiology, and End Results (SEER) Program database, the 10-year
cumulative incidence of SPMs was 12.7%, significantly higher than that expected in the general US
population.5
Ruxolitinib (RUX) is an oral JAK inhibitor (JAKi) approved for International Prognostic Scoring System
(IPSS)/Dynamic IPSS (DIPSS) intermediate- and high-risk myelofibrosis (MF)6,7 and for inadequately
controlled PV. More than 2600 RUX-treated MF patients have been prospectively observed for at least
2 years within the 2 pivotal COMFORT trials8,9 and the expanded-access JUMP trial.10,11 Safety data
from these trials underline a possibly increased incidence of nonmelanoma skin cancers (NMSCs), but
no significant increase of lymphoproliferative neoplasms, similarly to what occurs in PV.12,13
Recently, Porpaczy et al alerted, however, on the possible 16-fold increased risk of developing
aggressive lymphomas in MPN patients treated with JAKis, especially in the presence of a preexisting
B-cell clone.14 The publication included a total of 1555 MPN patients, 126 of whom were treated with
a JAKi (ruxolitinib, gandotinib, fedratinib, momelotinib), obtained assembling 2 broad academic data sets.
In the well-described Viennese cohort, 3 of 31 MF patients treated with JAKi developed lymphomas.
Median time from JAKi initiation to lymphoma diagnosis was 25 months.
Subsequent analyses of other large academic data sets did, however, not confirm an increased risk
of aggressive lymphoma development under JAKis in MPNs15,16 and in post-PV and post-ET MF
(secondary MF [SMF]).17 These contradictory results were derived either from clinical trials with strict
eligibility criteria, possibly at the expense of uncertainty about the generalizability of results, or from highly
selected data sets of patients evaluated at referral centers, thus highlighting the need for real-world data
(RWD).
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Table 1. Main patient characteristics in the whole cohort and according to post-RUX SPM occurrence
All, n 5 219 No SPM post-RUX, n5 201 SPM post-RUX, excluding NMSC, n5 9 NMSC post-RUX, n5 9
Sex, M/F 129/90 116/85 6/3 7/2
Median age at diagnosis (range), y 62 (19-83) 61 (19-83) 62 (46-69) 67 (35-73)
Diagnosis
PMF 99 90 6 3
Post-ET MF 37 34 2 1
Post-PV MF 83 77 1 5
Mutational status
JAK2 mutated 160 147 4 9
CALR mutated 33 30 3 0
MPL mutated 5 4 1 0
Triple negative 7 6 1 0
Comutated 3 3 0 0
NA* 11 11 0 0
IPSS score at diagnosis (for PMF patients only, available
in 89)
Low 27 26 1 0
Intermediate-1 20 18 0 2
Intermediate-2 22 19 2 1
High 20 19 1 0
MYSEC-PM score at diagnosis (for SMF patients only,
available in 107)
Low 26 25 1 0
Intermediate-1 54 48 1 5
Intermediate-2 20 18 1 1
High 7 7 0 0
Median time from diagnosis to RUX start (range), mo 30 (0-294) 30 (0-294) 30 (8-149) 38 (1-59)
At RUX start
Median age (range), y 66 (24-84) 65 (24-84) 67 (49-74) 70 (67-78)
Median WBC (range), 3109/L 11.0 (1.8-70.0) 11.1 (1.8-70.0) 12.9 (5.3-31.1) 10.3 (4.2-23.3)
Median Hb (range), g/dL 10.4 (5.8-16.0) 10.4 (5.8-16.0) 10.0 (8.8-12.4) 11.1 (8.9-13.5)
Median PLT (range), 3109/L 213 (14-1425) 212 (14-1425) 387 (75-503) 249 (61-570)
Median peripheral blood blasts (range), % 1 (0-12) 1 (0-12) 2 (0-6) 1 (0-6)
Constitutional symptoms, absent/present/NA 72/141/6 67/129/5 2/7/0 3/5/1
Median palpable splenomegaly from lcm (range), cm 10.0 (0.0-34.0) 10.0 (0.0-34.0) 9.5 (5.0-24.0) 10.0 (5.0-19.0)
DIPSS score, for PMF patients only, available in 95
Low 3 3 0 0
Intermediate-1 36 36 0 0
Intermediate-2 41 34 5 2
High 15 13 1 1
Median follow-up after RUX start (range), mo 24 (0-110) 23 (0-110) 31 (12-75) 39 (7-56)
Median RUX exposure (range), mo 18 (0-110) 17 (0-110) 31 (12-75) 39 (7-56)
SPM pre-RUX, all types 20 16 3 1
SPM pre-RUX, excluding NMSC 16 14 2 0
DIPSS, Dynamic International Prognostic Scoring System; ET, essential thrombocythemia; F, female; Hb, hemoglobin; IPSS, International Prognostic Scoring System; lcm, left costal
margin; M, male; MF, myelofibrosis; MYSEC-PM, Myelofibrosis Secondary to PV and ET–Prognostic Model; NA, not available; NMSC, nonmelanoma skin cancer; PLT, platelet; PMF, primary
myelofibrosis; PV, polycythemia vera; RUX, ruxolitinib; SMF, secondary myelofibrosis; SPM, second primary malignancy; WBC, white blood cell.
*NA includes patients who have tested 1 or 2 driver mutations and resulted unmutated but cannot be defined "triple negative" (TN) because not all 3 driver mutations have been studied,
and patients for whom the driver mutational status is not available.
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We consequently set out to assess the occurrence of SPMs,
including lymphoproliferative neoplasms, in RUX-treated MF patients
on the basis of RWD provided by the health authority of the
Lombardy Region, integrated with institutional data.
Methods
The Italian health care service is regionally based and characterized
by universal coverage. Drugs are delivered by each regional health
authority, and most newly approved high-cost treatments, like RUX,
are subject to longitudinal monitoring. This allows for an accurate
identification of all individual patient prescriptions in the region. In
addition, Lombardy, a region of roughly 10 million individuals, has
a well-established network for hematology (Rete Ematologica
Lombarda [REL]), with a specific commission for MPNs. Within
the REL, and on the basis of RWD provided by the health
authority of the Lombardy region, we conducted an ambispective
observational study (RUXOREL-MF, clinicaltrials.gov identifier
NCT03959371) including all MF patients treated with RUX
provided by the regional health care system, that is, 219 subjects
regularly followed at 16 centers. These data have been inte-
grated with clinical and genetic data from each center.
The study was approved by the review board of each institution
and conducted in accordance with the Declaration of Helsinki.
Incidence rates were computed from the number of events vs
the time at risk after RUX start. Comparisons with the general
population were performed via Poisson models on age- and sex-
matched incidence ratios, standardized with respect to available
population data for Lombardy (2003-2007) provided in Cancer
Incidence in Five Continents Volume X (CI5-X) tables (Interna-
tional Agency for Research on Cancer).18 Comparisons with RUX-
naive MF patients (n 5 246, derived from the Varese institutional
database; main patient characteristics reported in supplemental
Table 1) were performed via Poisson models with adjusted incidence
rates. Time-to-event analyses were performed using Aalen-Johansen
estimators of cumulative incidences, log-rank tests, and cause-specific
Cox models based on time elapsed after RUX start.
Results and discussion
Demographics of the 219 patients treated with RUX and included in
the study are summarized in Table 1. Among these, we recorded 23
SPMs (of which 13 NMSCs) in 18 subjects (5 patients experienced
2 SPMs). A direct comparison of main patient characteristics
according to occurrence of an SPM is also summarized in Table 1.
Median follow-up from diagnosis was 58.8 months (interquartile
range [IQR], 33.9-96.4) and median duration of MF before RUX
start was 30.1 months (IQR, 5.7-62.2). Median follow-up from
RUX start was 24.0 months (IQR, 12.3-40.4), whereas median RUX
exposure was 18.2 months (IQR, 8.3-37.2). At the time of data
cutoff, that is, 4 June 2019, 146 patients (66.7%) are still on
treatment and 50 died (23.0%). Cause of death was related to the
SPM in 2 patients. Median estimated overall survival from diagnosis
and from RUX start was 240.0 and 78.7 months, respectively.
Distribution of SPMs during the course of the disease was as
follows: 24 cases were reported prior to RUX start (no case of
lymphoma) and 23 cases occurred after RUX start (lung, 1;
breast, 2; prostate, 2; bladder, 1; melanoma, 1; multiple myeloma, 1;
chronic myeloid leukemia, 1; hepatobiliary carcinoma, 1; NMSC, 13).
None of the 219 RUX-treated patients developed a lymphoma. The
incidence rate of SPMs post-RUX was 4.3 per 100 patient-years
(95% confidence interval [CI], 2.7-6.4), whereas it was 1.9 per
100 patient-years (95%CI, 0.9-3.4), when excluding NMSCs from
the analysis. Median time to SPM diagnosis after RUX start was
16.9 months (IQR, 6.9-21.5) and 19.8 months (IQR, 16.3-36.7)
when excluding NMSCs. Cumulative incidence of SPMs (exclud-
ing NMSCs) after RUX start is reported in Figure 1. Patients with
an SPM pre-RUX were at higher risk of developing an SPM
post-RUX (hazard ratio [HR], 3.6; 95% CI, 1.2-11.2; P 5 .02).
Significance was lost if the analysis excluded NMSCs (HR, 3.8;
95% CI, 0.8-19.0; P 5 .08). The incidence of SPMs in our cohort
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Figure 1. Cumulative incidence of SPMs (excluding
NMSCs) after RUX start.
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was significantly higher than the incidence of cancer in the general
population (standardized incidence ratio: 1.7; 95% CI, 1.02-2.6;
P 5 .026). The trend holds true for both males and female
patients, although without statistical significance likely due to the
smaller number of cases. Importantly, there is no significant
difference if the analysis excludes NMSCs (namely ICD-10-CM
diagnosis code C44; HR, 1.0; 95% CI, 0.5-1.8; P 5 1.0). Finally,
when comparing the incidence of SPMs in our RWD collection
with that in 246 JAKi-naive MF patients, we found a trend toward
an enrichment of SPMs in the RUX-treated group (4.3 vs 2.3 per
100 patient-years, rate ratio test: ratio, 1.84; 95% CI, 0.99-3.43;
P 5 .06), which again ceased to be evident when NMSCs were
excluded from the analysis (1.9 vs 1.3 per 100 patient-years; ratio,
1.41; 95% CI, 0.56-3.49; P 5 .53). Even after adjusting the
comparison for type of diagnosis (PMF vs SMF) and for disease
severity (IPSS for PMF and Myelofibrosis Secondary to PV and
ET–Prognostic Model [MYSEC-PM] for SMF), we did not find
a significant difference in SPM incidence between RUX-treated
and RUX-naive patients (rate difference, 1.08 per 100 patient-
years; P 5 .41; supplemental Results).
In conclusion, our RWD offer a unique opportunity to provide real-
world evidence on the incidence of SPMs in MF patients receiving
RUX. In our cohort, no case of lymphoma was registered with
a median follow-up after RUX start, which, albeit relatively short,
matches the median time to lymphoma occurrence reported by
Porpaczy et al. Furthermore, when excluding NMSCs, RUX-treated
MF patients do not seem to be at a higher risk of SPMs with respect
to the general population and to a cohort of RUX-naive MF patients.
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